ReviewTherapeutic advances in chronic disease2022
Application of fucoidan as treatment for cardiovascular and cerebrovascular diseases.
Review in Therapeutic advances in chronic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 43 citations in OpenAlex.
- Investigating fucoidan blend supplementation and resistance training in humans: a parallel randomized controlled trial design.Scientific reports · 2025Trial
- Fucoidans as multifunctional marine polysaccharide platforms: From nutritional supplements to advanced drug delivery for cancer therapy.International journal of pharmaceutics: X · 2026Review
- Fucoidan for Lung Cancer Therapy: A Review of Classification, Mechanisms, and Preclinical Studies.ACS omega · 2025Review
- Nutritional and Antioxidative Benefits of Dietary Macroalgae Supplementation in Weaned Piglets.Animals : an open access journal from MDPI · 2024Article
- Exploring carbohydrate extraction from biomass using deep eutectic solvents: Factors and mechanisms.iScience · 2023Review
- P-Selectin mediates targeting of a self-assembling phototherapeutic nanovehicle enclosing dipyridamole for managing thromboses.Journal of nanobiotechnology · 2023Article
- Review
- A Combination of Deep-Sea Water and Fucoidan Alleviates T2DM through Modulation of Gut Microbiota and Metabolic Pathways.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Nano-Sized Fucoidan Interpolyelectrolyte Complexes: Recent Advances in Design and Prospects for Biomedical Applications.International journal of molecular sciences · 2023Review
- A Dietary Supplement Containing Fucoidan Preserves Endothelial Glycocalyx through ERK/MAPK Signaling and Protects against Damage Induced by CKD Serum.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucoidan is a marine polysaccharide. In recent years, fucoidan has attracted wide-scale attention from the pharmaceutical industries due to its diverse biological activities such as lipid-lowering, anti-atherosclerosis, and anticoagulation. This review clarifies the pharmacological effects of fucoidan in the treatment of human cardiovascular and cerebrovascular diseases. Fucoidan exerts a hypolipidemic effect by increasing the reverse transport of cholesterol, inhibiting lipid synthesis, reducing lipid accumulation, and increasing lipid metabolism. Inflammation, anti-oxidation, and so on have a regulatory effect in the process of atherosclerosis endothelial cells, macrophages, smooth muscle cells, and so on; fucoidan can not only prevent thrombosis through anticoagulation and regulate platelet activation, but also promote the dissolution of formed thrombi. Fucoidan has a neuroprotective effect, and also has a positive effect on the prognosis of the cardiovascular and cerebrovascular. The prospects of applying fucoidan in cardio-cerebrovascular diseases are reviewed to provide some theoretical bases and inspirations for its full-scale development and utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.